Delving into the Latest Updates on JSW Lifesciences GmbH with Synapse

A multicentre double-blind, placebo-controlled, randomised, parallel-group study to evaluate the efficacy and safety of Lornoxicam in patients with mild to moderate probable Alzheimer’s Disease.

开始日期2009-10-30

申办/合作机构

JSW Lifesciences GmbH

NCT01117948 / Terminated临床2期

A Multicentre Double-blind, Placebo-controlled, Randomised, Parallel-group Study to Evaluate the Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease.

Study title: A multicentre double-blind, placebo-controlled, randomised, parallel-group study to evaluate the safety and efficacy of Lornoxicam in patients with mild to moderate probable Alzheimer's Disease.
Study phase: II
Indication: Alzheimer´s Disease
Investigational product, dose schedule and route of administration: Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
Reference product, dose, schedule and route of administration: Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.

开始日期2009-09-01

申办/合作机构

JSW Lifesciences GmbH

NCT00840671 / Completed临床3期

A Prospective, Randomised, Placebo Controlled, Double Blind Trial About Safety and Efficacy of Combined Treatment With Alteplase (Rt-PA) and Cerebrolysin® in Acute Ischemic Hemispheric Stroke

It should be shown that Cerebrolysin in combination with Alteplase, the medication that should recover the blood flow through the brain, is an effective and save medication to treat ischeamic stroke.

开始日期2005-10-01

申办/合作机构

EVER Neuro Pharma GmbH

[+1]

100 项与 JSW Lifesciences GmbH 相关的临床结果

登录后查看更多信息

0 项与 JSW Lifesciences GmbH 相关的专利（医药）

登录后查看更多信息

3

项与 JSW Lifesciences GmbH 相关的文献（医药）

2010-12-01·Neuron

The ACAT Inhibitor CP-113,818 Markedly Reduces Amyloid Pathology in a Mouse Model of Alzheimer's Disease

作者: Huttunen, Henri J. ; Puglielli, Luigi ; Kovacs, Dora M. ; Domnitz, Sarah B. ; Eckman, Christopher B. ; Frosch, Matthew P. ; Hofmeister, Alexander ; Hutter-Paier, Birgit ; Windisch, Manfred ; Kim, Doo-Yeon ; Moir, Robert D.

On page 230, Figure 2 is incorrect; the correct version of the figure is given.

2005-10-01·Journal of Neural Transmission4区 · 医学

N-PEP-12 – a novel peptide compound that protects cortical neurons in culture against different age and disease associated lesions

4区 · 医学

Article

作者: M. Windisch ; E. Grygar ; H. Moessler ; B. Hutter-Paier ; E. Doppler

The neuroprotective potency of N-PEP-12, a novel, proprietary compound consisting of biopeptides and amino acids was investigated. Lesion models have been applied in neuronal cultures of embryonic chicken cortex, pre-treated with N-PEP-12 from the first day onwards. On day 8 in vitro neurons were lesioned and cell viability was measured 24 and 48 hours later. To simulate acute brain ischemia, cytotoxic hypoxia was induced by sodium cyanide or by iodoacetate and excitotoxicity by L-glutamate. Ionomycin for up to 48 hours induced calcium overload. The cytoskeleton was disrupted by addition of colchicine. N-PEP-12 shows dose-dependent neuroprotection in all different models. The effect size depends on the recovery time but also on the extent of the lesion. In cases of mild to moderate lesion pronounced dose-dependent effects could be demonstrated. This indicates that chronic exposure to N-PEP-12 is able to prevent neuronal cell death associated to conditions occurring during normal aging and neurological disorders like ischemic stroke, hypoxia, brain trauma, or AD.

2002-01-01·Ageing and Dementia Current and Future Concepts

Current drugs and future hopes in the treatment of Alzheimer’s disease

Review

作者: M. Windisch ; E. Schreiner ; B. Hutter-Paier

In spite of several years of experience with the use of cholinesterase inhibitors for treatment of symptoms of Alzheimer's disease their influence on disease progression remains still unclear. New cholinesterase inhibitors should provide an additional neuroprotective activity, because only substances which stop neuronal death can influence disease progression. New treatment strategies are focusing on amyloid processing, preventing the occurrence of toxic A beta(1-42) peptide. These procedures include the vaccination trials, but their clinical usefulness has to be proven. Also strategies focussing on neurofibrillary pathologies should be explored in detail. Drug development for Alzheimer's disease should include all pathological events associated with neurodegeneration, like oxidative stress, neuroinflammation or disturbances in growth factor signaling. Abnormal protein aggregation as a common feature of different neurodegenerative diseases might also be a promising drug target. Beside beta sheet breakers directed against beta-amyloid deposition the endogenous protein beta-synuclein or derivatives of it might be able to counteract aggregation of alpha-synuclein as well as of amyloid beta protein. Interaction with alpha-synuclein deserves special attention because it might be an early step of synaptic degeneration. Due to the complexity of the disease combination of different drugs might be the most promising way to go. The parallel development of early biological markers should enable intervention in pre-symptomatic disease stages.

1

项与 JSW Lifesciences GmbH 相关的新闻（医药）

2023-01-25

·FierceBiotech

TFS HealthScience snaps up niche CRO Appletree in ophthalmology expansion

Switzerland-based Appletree has a presence in 11 European countries. Sweden’s TFS HealthScience snapped up niche CRO Appletree CI Group for an undisclosed price in a move to expand into the growing ophthalmology arena. TFS, which is based in Lund, Sweden with operations throughout Europe and North America said in a Jan. 23 release that the acquisition will also extend its geographic reach as well as provide additional expertise in dermatology, medical devices and pediatric studies. Switzerland-based Appletree, which was founded in 2013 in the wake of the merger of Clinical Investigations and Appletree AG, has a presence in 11 European countries and also has expertise in regulatory affairs. "The strategic acquisition of Appletree will complement TFS HealthScience’s mission to be a market leader in ophthalmology research,” TFS CEO Bassem Saleh said in the release. “In a targeted business shift toward ophthalmology expertise, the company launched its elite site network initiative and site liaison services, which will shift the industry’s approach to ophthalmology clinical trial delivery.” TFS cited a recent study published in The Journal of American Medicine that estimates research funding for ophthalmology grew 203% from 2014 to 2020. The study also forecast the global ophthalmology drug market to hit $60.3 billion by 2028, an increase of 6.4% from 2021 figures.